# Moderna QA Intel - Executive Summary for Outreach

## WHAT MAKES MODERNA SPECIAL (Testing-Wise)

Moderna isn't a typical biotech. They're a **digital biotech** attempting to rebuild from the ground up using AI. This creates unusual QA pain.

---

## THE 3 BIG INFLECTION POINTS

### 1. AI EXPLOSION (3,000+ custom GPTs)
- Early 2024: Deployed ChatGPT Enterprise at scale
- Current: 3,000+ custom GPTs embedded across company
- Implication: **Testing traditional QA frameworks can't scale to validate AI workflows**
- Pain: How do you test 3,000 different AI agent outputs? Traditional test automation breaks.

### 2. BENCHLING PLATFORM ROLLOUT (May 2025 - Happening NOW)
- R&D scientists moving to unified AI-ready Benchling platform
- 100+ scientists expecting validated workflows
- Fresh platform = **no mature test suite exists yet**
- Testing challenges: Instrument data integration, ML model validation, workflow automation

### 3. MANUFACTURING TEST NIGHTMARE (Multi-facility)
- Moderna manufactures through: Thermo Fisher, Catalent, Sanofi (3+ partners)
- Each facility has its own systems, validation requirements
- Seasonal production = test flakiness spikes
- Pain: **Coordinating test suites across 3+ partner facilities is coordination hell**

---

## INSIDER SIGNALS SHOWING REAL PAIN

### Signal #1: "Digital Technology" Reporting Structure
May 2025: Moderna merged HR and IT under single leader. This signals:
- Automation is now strategic (embedded in org structure)
- Legacy test processes are candidates for replacement
- Appetite for new QA approaches to support AI

### Signal #2: Atlanta Digital Solutions Hub Growing
150-200 person team hired 2022-2026 to manage:
- Finance systems
- HR systems
- Procurement systems
- **"Digital solutions"** (testing these is their job)

This is active hiring, which means:
- New QA team being built
- Fresh budget for QA tools/approaches
- No entrenched existing solution

### Signal #3: Benchling Integration (Official Partner Announcement)
May 2025 press release = Moderna betting company on Benchling success. This means:
- Testing Benchling integration is non-negotiable
- QA team is ramping up for this
- Wade Davis (SVP) quote: "AI is creating new ways of working" = testing approaches must change

---

## WHAT THEIR QA TEAMS ARE STRUGGLING WITH (INFERRED)

| Pain | Why It Matters | Testsigma Angle |
|------|---------------|-----------------|
| **Test Maintenance Across 3 Manufacturing Sites** | Locators break when UI updates, especially at partner facilities | Self-healing = 90% maintenance reduction |
| **Testing AI-Generated Workflows** | 3,000+ GPTs need validation; Selenium/TOSCA can't test AI behavior | AI-powered test generation = test what AI creates |
| **Benchling Integration Testing** | New platform, complex data flows (instruments + ML + workflows) | NLP test generation = faster test suite creation |
| **Test Brittleness in Seasonal Manufacturing** | Production ramps = UI changes spike = test failures spike | Self-healing maintains tests through rapid changes |
| **No Unified Test Platform** | Using TOSCA + Selenium + custom scripts = maintenance chaos | Unified platform consolidates tools |

---

## THE PRIMO PROSPECT PROFILE

### Best Target: QA Director/Head at Moderna

**Where they are:** Norwood, MA HQ OR Atlanta digital hub
**What they care about:**
- Regression testing keeping pace with seasonal manufacturing (it's not)
- Benchling rollout test coverage (it doesn't exist yet)
- Cross-facility test synchronization (manual nightmare)
- FDA compliance testing (changing with new risk-based guidance)

**What would get them to take a call:**
"Manufacturing rollout across three facilities + new Benchling platform = your QA team's juggling more than it can handle. Curious how you're staying on top of regression cycles with seasonal production?"

### Secondary Target: SDET/Automation Engineer

**What they care about:**
- Framework fragmentation (Selenium + TOSCA + custom scripts)
- Test maintenance consuming 70% of their time
- Can't scale testing to 3,000+ AI workflows
- Benchling integration testing (non-standard requirements)

**What would get them to take a call:**
"Benchling + custom ML models + manufacturing automation = three test domains. Which framework was built to handle that combo?"

---

## PROOF POINTS THAT RESONATE

### For Manufacturing Pain (Regression Cycles)
**Sanofi: 3 days → 80 minutes regression time with self-healing**
- Same industry (pharma/vaccine)
- Same pain (manufacturing validation)
- Same regulatory environment (FDA)
- Numbers are concrete (not "significantly reduced")

### For R&D Scale (100+ Scientists)
**Medibuddy: 2,500 tests, 50% maintenance cut**
- Healthcare industry (close to Moderna)
- Scaling coverage without scaling QA team
- Tangible maintenance reduction

### For Enterprise Scale (Atlanta Hub)
**Fortune 100: 3X productivity increase**
- Multi-system testing (like Atlanta's digital solutions)
- Enterprise complexity (finance, HR, procurement systems)

---

## THE CONVERSATION ANGLE (Not the Product Pitch)

**Don't say:** "Testsigma uses AI to generate tests..."

**Say:** "Your team's managing Benchling rollout to 100+ scientists + validating across Thermo Fisher, Catalent, and Sanofi. That's three different test domains. How are you handling that without test fragmentation?"

**Listen for:** "Yeah, we're running TOSCA for manufacturing, Selenium for... [fractures from there]"

**Then pivot:** "A lot of teams in regulated environments found that fragmenting tools made their maintenance costs explode once they started scaling. Especially with seasonal production changes. That resonate?"

**If yes:** "Would seeing how other pharma teams consolidated this be worth 15 minutes?"

---

## WHAT TO RESEARCH ON THEIR LINKEDIN

### For QA Director
- How long in role? (New leaders = 90-day evaluation window, more open to new tools)
- Background: QA + manufacturing + compliance? (Signal they feel the pain)
- Current company before Moderna? (If pharma = highly relevant pain match)

### For SDET
- What tools do they mention? (Selenium? TOSCA? That's your hook)
- Projects listed? (Manufacturing systems? Benchling? Direct pain signal)
- How long at Moderna? (New = more open; 3+ years = embedded in current stack)

---

## KEY STATS TO HAVE READY

- Moderna workforce: **5,800 employees**
- Custom GPTs deployed: **3,000+**
- Manufacturing partners: **3+ (Thermo Fisher, Catalent, Sanofi)**
- Atlanta hub headcount: **150-200 (2022-2026)**
- Benchling expansion: **May 2025** (recent signal)
- dbt Mesh implementation: **Already live** (data infrastructure modernizing)

---

## WHAT NOT TO MENTION

- Moderna's stock price or investor news (not their problem)
- COVID vaccine as primary business (they're pivoting to RSV, MPOX, other programs)
- Specific tool comparisons (don't trash TOSCA; let them say "we use TOSCA")
- Competitor tools by name unless they bring it up

---

## THE 60-SECOND MENTAL MODEL FOR CALLING

**Moderna's reality right now:**

1. **They're scaling AI aggressively** (3,000+ GPTs) but testing frameworks can't scale with it
2. **They're launching a major platform** (Benchling, May 2025) with no mature test suite
3. **They're manufacturing at scale** across 3+ partner facilities with fragile test suites
4. **Their regulatory environment is shifting** (FDA risk-based guidance) = appetite for new approaches

**Your relevance:**

- You help companies test at the scale Moderna is trying to reach
- You consolidate fragmented testing tools (Testsigma vs. TOSCA + Selenium)
- You handle self-healing for brittle environments (manufacturing QA is brittle)
- You align with their AI-first strategy (NLP test generation, AI agents)

**The ask:**

15 minutes to understand how manufacturing validation + platform modernization + AI scaling is hitting their timeline. That's it.

---

## QUICK REFERENCE: OUTREACH ANGLES BY ROLE

### QA Director at Norwood/Atlanta
**Subject:** Manufacturing + Platform Testing
**Angle:** Regression cycles, facility coordination, Benchling readiness
**Proof:** Sanofi 3→80 min
**Ask:** "Worth 15 min to compare regression testing approaches?"

### SDET/QA Engineer
**Subject:** Test Maintenance at Scale
**Angle:** Framework fragmentation, test brittleness, tool consolidation
**Proof:** Medibuddy 50% maintenance cut
**Ask:** "Happy to share what other medical device/pharma engineers have learned?"

### Atlanta Digital Solutions Manager
**Subject:** Enterprise Scale Testing
**Angle:** Finance/HR/procurement systems, multi-system validation, velocity
**Proof:** Fortune 100 3X productivity
**Ask:** "Would exploring how other enterprise teams scale without proportional QA headcount be useful?"

---

## FINAL POSITIONING

Moderna is in **transition state**:
- Old testing approaches (manual, tool-fragmented, brittle) breaking
- New requirements (AI validation, platform scale, multi-facility) emerging
- Fresh org being built (Atlanta hub) = no entrenched vendor lock-in yet
- Regulatory environment shifting = appetite for new strategies

**This is the ideal prospect window.**

If you wait 18 months, they'll have:
- Picked their testing stack
- Embedded their processes
- Locked in vendor relationships

Hit them **now** while Benchling is rolling out and Atlanta is hiring.
